Stockscreener 앱 받기
131.18
0.74%
0.96
전일 마감가:
$130.22
열려 있는:
$131.25
하루 거래량:
753.45K
Relative Volume:
0.67
시가총액:
$13.19B
수익:
$2.86B
순이익/손실:
$478.60M
주가수익비율:
28.10
EPS:
4.6676
순현금흐름:
$748.70M
1주 성능:
-0.20%
1개월 성능:
+2.74%
6개월 성능:
-7.27%
1년 성능:
+28.94%
1일 변동 폭
$129.89
$131.43
1주일 범위
$127.76
$134.11
52주 변동 폭
$101.15
$160.18
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
131.18 | 13.10B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
16.60 | 53.90B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.52 | 49.70B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.36 | 42.40B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.22 | 36.43B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
574.29 | 25.13B | 3.18B | 1.33B | 1.04B | 27.90 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN
Neurocrine reports sustained glucocorticoid reductions in CAH study By Investing.com - Investing.com South Africa
Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia - ChartMill
NBIX Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus
How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing - Stock Traders Daily
Why this Bay Area company took a buyout offer that was nearly $2 billion less than an earlier bid - The Business Journals
3 Reasons Growth Investors Will Love Neurocrine (NBIX) - Yahoo Finance
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $185 - Moomoo
Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet - Zacks Investment Research
Lobbying Update: $940,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative
Neurocrine is making a $2.9 billion bet on a new kind of drug - MSN
Morgan Stanley Maintains Neurocrine Biosciences (NBIX) Overweight Recommendation - MSN
Neurocrine Biosciences (NASDAQ: SLNO) offers $53.00 per share cash to Soleno - Stock Titan
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Unveiling a 39.92% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity - simplywall.st
A Look at Neurocrine Biosciences Inc (NBIX) After 3.8% Gain -- G - GuruFocus
Neurocrine's Acquisition Impacts Soleno Therapeutics (SLNO) Rati - GuruFocus
How New Real-World INGREZZA Data Versus AUSTEDO XR Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Hold at Zacks Research - MarketBeat
Sumitomo Mitsui Trust Group Inc. Decreases Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Massachusetts Financial Services Co. MA Sells 10,415 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Q3 2025 Earnings Preview - MSN
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setup - ChartMill
Neurocrine Expands CNS Pipeline With Nxera Schizophrenia Trial And Milestones - Sahm
How Investors May Respond To Neurocrine Biosciences (NBIX) INGREZZA Real-World Persistence Edge Over AUSTEDO XR - Yahoo Finance
Is It Time To Reassess Neurocrine Biosciences (NBIX) After Its Recent Share Price Pullback? - Yahoo Finance
Real World INGREZZA Data May Support Neurocrine’s Tardive Dyskinesia Lead - Sahm
Neurocrine Biosciences (NBIX) Stock Price, News & Analysis - MarketBeat
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
Neurocrine Biosciences | DEF 14A: Definitive information statements - Moomoo
Form DEFA14A NEUROCRINE BIOSCIENCES - StreetInsider
Neurocrine Biosciences (NBIX) seeks approval for 4M-share equity plan boost - Stock Titan
Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock? - Zacks Investment Research
Neurocrine Biosciences identifies new CRF2 receptor agonists - BioWorld News
Robeco Institutional Asset Management B.V. Purchases 85,076 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking - MSN
Neurocrine Biosciences Inc (NBIX) Stock Up 3.6% and Still Undervalued -- GF Score: 96/100 - GuruFocus
Neurocrine Biosciences Inc (NBIX) Stock Up 3.6% and Still Underv - GuruFocus
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results - The AI Journal
Neurocrine to post Q1 results May 5, webcast starts at 4:30 ET - Stock Titan
Valbenazine Demonstrates Higher Persistence vs Deutetrabenazine in TD Patients - HMP Global Learning Network
INGREZZA shows higher treatment persistence than AUSTEDO XR in study - StreetInsider
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR - ChartMill
Soleno Therapeutics stock rallies 56.4% in a week: Here's why - MSN
Burney Co. Cuts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
FDA’s FIH plans. Plus: billion-dollar deals, funds — a BioCentury podcast - BioCentury
Investment Recap: Does Neurocrine Biosciences Inc have pricing power2026 Volume Leaders & Weekly High Return Stock Forecasts - baoquankhu1.vn
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ABERNETHY MATT | Chief Financial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,133 |
0 |
39,230 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
3,352 |
0 |
7,969 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
1,600 |
0 |
6,313 |
| Gano Kyle | Chief Executive Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,807 |
0 |
147,610 |
| Gano Kyle | Chief Executive Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
4,907 |
0 |
146,661 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
5,407 |
0 |
21,066 |
| Onyia Jude | Chief Scientific Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,560 |
0 |
18,537 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,044 |
0 |
56,664 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,005 |
0 |
54,760 |
| Cooke Julie | Chief Human Resources Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
2,911 |
0 |
30,395 |
3.13%
0.66%
자본화:
|
볼륨(24시간):